Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neosil in Chronic Telogen Effluvium
NCT03659201Phase 4Completed
- Sponsor
- EMS
- Start
- Sep 2018
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (3 arms), sponsored by EMS. Primary endpoint: Hair density at 24 weeks. Started Sep 2018; status: completed.
Beyond the preview
Go deeper on NCT03659201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659201.